AKT1 and cholangiocarcinoma: Furthermore, pretreatment of Cholangiocarcinoma cells with the 740 y-p (PI3K agonist) abolished the effects of Tan-IIA on the restrain PI3K, p-Akt, mTOR, and p-mTOR in Cholangiocarcinoma cells (Fig. 3D–F).